Loading patent…
AssigneeEwha University-Industry Collaboration Foundation
InventorsLak Shin JEONG, Sang Kook LEE, Hwa Jin CHUNG, Hyuk Woo LEE
Estimating the term…
The present invention relates to a method by use of a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less toxic than conventional A3 adenosine agonists, and thus is useful for prevention or treatment of inflammatory disease. In addition, it more selectively inhibits the growth of androgen receptor-dependent or independent prostate cancer cells than other A3 adenosine receptor agonists and thus is useful for prevention or treatment of colorectal cancer or prostate cancer.
A method for treating prostate cancer by use of a pharmaceutical composition comprising, as an active ingredient, an A3 adenosine receptor agonist represented by the following formula 1 or a pharmaceutically acceptable salt thereof, by administering the active ingredient at a dose of 1˜50 mg/kg once or several times a day:
Dependencies are inferred from the claim text.